PSPhuwanat Sakornsakolpat

Phuwanat Sakornsakolpat

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Phuwanat Sakornsakolpat has a total of 75 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Relative Contributions of Family History and a Polygenic Risk Score on COPD and Related Outcomes: COPDGene and ECLIPSE studies

    by Matthew Moll, Sharon M. Lutz, Auyon J Ghosh, Phuwanat Sakornsalkolpat, Craig Hersh, Terri H Beaty, Frank Dudbridge, Martin D Tobin, Murray A Mittleman, Edwin K. Silverman, et al.

    Introduction: Family history is a risk factor for chronic obstructive pulmonary disease (COPD). We previously developed a COPD risk score from genome-wide genetic markers (polygenic risk score, or PRS). Whether the PRS and family history provide complementary or redundant information for predicting COPD and related outcomes is unknown. Methods: We assessed the predictive capacity of family history and PRS on COPD and COPD-related outcomes in European ancestry subjects from the COPDGene and ECLIPSE studies. We also performed interaction and mediation analyses. Results: In COPDGene, family history and PRS were significantly associated with COPD in a single model (P FamHx = 1.6e-12; P PRS = 5.0e-92). Similar trends were seen in ECLIPSE. Area-under-the-receiver-operator-characteristic-curves (AUCs) for family history, PRS, and the combined predictors for COPD were 0.752, 0.798, and 0.803, respectively. The AUC for a model containing both family history and the PRS was significantly higher than models with PRS (p = 0.00035) or family history (p = 6.1e-29) alone. Both family history and PRS were significantly associated with BODE, SGRQ, and multiple measures of quantitative emphysema and airway thickness. There was a weakly positive interaction between family history and the PRS under the additive, but not the multiplicative scale (RERI = 0.48, p=0.04). Mediation analysis found 16.5% of the effect of family history on risk for COPD was mediated through the PRS [95% CI: 9.4%-24.3%]. Conclusion: Family history and the PRS provide complementary information for predicting COPD and related outcomes. Future studies can address the impact of obtaining both measures in clinical practice.

  • Open Access

    Analysis of genetically driven alternative splicing identifies FBXO38 as a novel COPD susceptibility gene

    by Aabida Saferali, Jeong H. Yun, Margaret M. Parker, Phuwanat Sakornsakolpat, Robert P. Chase, Andrew Lamb, Brian D. Hobbs, Marike H. Boezen, Xiangpeng Dai, Kim de Jong, et al.

    While many disease-associated single nucleotide polymorphisms (SNPs) are associated with gene expression (expression quantitative trait loci, eQTLs), a large proportion of complex disease genome-wide association study (GWAS) variants are of unknown function. Some of these SNPs may contribute to disease by regulating gene splicing. Here, we investigate whether SNPs that are associated with alternative splicing (splice QTL or sQTL) can identify novel functions for existing GWAS variants or suggest new associated variants in chronic obstructive pulmonary disease (COPD).RNA sequencing was performed on whole blood from 376 subjects from the COPDGene Study. Using linear models, we identified 561,060 unique sQTL SNPs associated with 30,333 splice sites corresponding to 6,419 unique genes. Similarly, 708,928 unique eQTL SNPs involving 15,913 genes were detected at 10% FDR. While there is overlap between sQTLs and eQTLs, 60% of sQTLs are not eQTLs. Co-localization analysis revealed that 7 out of 21 loci associated with COPD (p−6) in a published GWAS have at least one shared causal variant between the GWAS and sQTL studies. Among the genes identified to have splice sites associated with top GWAS SNPs was FBXO38, in which a novel exon was discovered to be protective against COPD. Importantly, the sQTL in this locus was validated by qPCR in both blood and lung tissue, demonstrating that splice variants relevant to lung tissue can be identified in blood. Other identified genes included CDK11A and SULT1A2.Overall, these data indicate that analysis of alternative splicing can provide novel insights into disease mechanisms. In particular, we demonstrated that SNPs in a known COPD GWAS locus on chromosome 5q32 influence alternative splicing in the gene FBXO38.Author Summary: While it is known that chronic obstructive pulmonary disease (COPD) is caused in part by genetic factors, few studies have identified specific causative genes. Genetic variants that alter the expression levels of genes have explained part of the genetic component of COPD, however, there are additional genetic variants with unknown function. In some genes the protein coding sequence can be altered by a mechanism known as RNA splicing. We hypothesized that some genetic variants that are associated with risk of COPD contribute to the disease by altering RNA splicing. In this study, we identified genetic variants that are associated both with COPD risk and RNA splicing. In particular, we found that a COPD associated variant of previously unknown function may contribute to the inclusion of a new exon in the FBXO38 gene. These finding are significant because they indicate that analysis of RNA splicing can help identify genes that contribute to disease.


  • Open Access

    Expanded genetic landscape of chronic obstructive pulmonary disease reveals heterogeneous cell type and phenotype associations

    by Phuwanat Sakornsakolpat, Dmitry Prokopenko, Maxime Lamontagne, Nicola F. Reeve, Anna L. Guyatt, Victoria E. Jackson, Nick Shrine, Dandi Qiao, Traci M. Bartz, Deog Kyeom Kim, et al.

    Summary: Chronic obstructive pulmonary disease (COPD) is the leading cause of respiratory mortality worldwide. Genetic risk loci provide novel insights into disease pathogenesis. To broaden COPD genetic risk loci discovery and identify cell type and phenotype associations we performed a genome-wide association study in 35,735 cases and 222,076 controls from the UK Biobank and additional studies from the International COPD Genetics Consortium. We identified 82 loci with P value < 5×10 −8 ; 47 were previously described in association with either COPD or population-based lung function. Of the remaining 35 novel loci, 13 were associated with lung function in 79,055 individuals from the SpiroMeta consortium. Using gene expression and regulation data, we identified enrichment for loci in lung tissue, smooth muscle and alveolar type II cells. We found 9 shared genomic regions between COPD and asthma and 5 between COPD and pulmonary fibrosis. COPD genetic risk loci clustered into groups of quantitative imaging features and comorbidity associations. Our analyses provide further support to the genetic susceptibility and heterogeneity of COPD.